News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Research Seen Risk to AstraZeneca PLC’s (JOBS) Nexium, Not Sanofi-Aventis (France)'s Plavix
March 4, 2009
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, March 4 (Reuters) - New research suggesting the blood thinner Plavix interacts badly with common heartburn drugs is a potential threat to AstraZeneca's (AZN.L) top-seller Nexium rather than Sanofi-Aventis's (SASY.PA) Plavix, analysts said.
Twitter
LinkedIn
Facebook
Email
Print
Europe
AstraZeneca
Sanofi
MORE ON THIS TOPIC
Insights
The Golden Triangle and the gaps: Rethinking UK biotech
June 25, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Insights
Beyond sunshine: Iberia’s biotech moment has arrived with developing capital networks
June 12, 2026
·
4 min read
·
Jennifer C. Smith-Parker
Insights
Portugal, Spain and the new biotech frontier
June 11, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Job Trends
May layoffs hit nearly 7,000, with most cuts from Takeda, BioNTech
June 11, 2026
·
3 min read
·
Angela Gabriel